Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMAGINE: Imetelstat and Azacitidine With or Without Venetoclax in Relapsed AML
NCT07320235Phase 1Recruiting
- Start
- Jan 2026
- Primary completion
- Jun 2030
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, open-label trial of imetelstat in acute myeloid leukemia (AML) (2 arms). Primary endpoint: Dose Limiting Toxicity at 28 days. Started Jan 2026; status: recruiting.
02
Drugs
imetelstat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07320235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07320235.